VSIR and prostate carcinoma: Among melanoma and prostate cancer patients treated with ipilimumab, VISTA expression is significantly upregulated on CD4+ T cells, CD8+ T cells and CD68+ macrophages, indicating that VISTA may contribute to mechanisms of resistance to checkpoint inhibitor therapies in these cancers (23, 24).